The use of iron hydroxypyrones such as ferric trimaltol, ferric tri-hydoxypyrone or a hydroxyl-4-pyrone such as 3-hydroxy-4-pyrone in the treatment or prevention of iron deficiency in subjects having elevated hepcidin levels such as those with anaemia of chronic disease or anaemia of chronic inflammation is disclosed.
